IP Verse

E R Squibb & Sons competitive analysis

Loading summary...

Latest patents of E R Squibb & Sons opposed by its competitors

Explore E R Squibb & Sons's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 6, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3597216
Aug 24, 2022Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof5
EP2905030
Nov 6, 2019Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) And Uses Thereof1
EP2439273
Feb 27, 2019Human Monoclonal Antibodies To Programmed Death 1(Pd-1) And Methods For Treating Cancer Using Anti-Pd-1 Antibodies Alone Or In Combination With Other Immunotherapeutics1
EP2501822
Aug 16, 2017Methods For Enhanced Protein Production2

Latest PTAB cases involving E R Squibb & Sons

Discover the latest PTAB cases involving E R Squibb & Sons, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing E R Squibb & Sons with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 6, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
E R SQUIBB & SONS - 9 - -
DF MP DORRIES FRANK MOLNIA & POHLMAN PATENTANWALTE RECHTSANWALTE PARG MBB12 - - -
KRAUS & LEDERER PARTGMBB68 - - -
REGENERON PHARMACEUTICALS3894931